QST Modeling Using BIOLOGXsym and Mechanistic Toxicity Data from a Biomimetic Liver Microphysiology System Predicts Increased Susceptibility to Nivolumab-Mediated Hepatotoxicity in MASLD Patients

Authors: Yang K, Clemens L, Vernetti L, Miedel MT, Castiglione MW, Taylor DL, Cruikshank A, Zhang L, Huizar F, C Vallejo, Shoda LKM, Beaudoin J
Conference: ASCPT
Keywords: BIOLOGXsym, hepatotoxicity, metabolic dysfunction-associated steatotic liver disease (MASLD)
Software: BIOLOGXsym

Background

Immune checkpoint inhibitor-related hepatotoxicity is a significant clinical concern. A retrospective analysis identified metabolic dysfunction-associated steatotic liver disease (MASLD) as a possible risk factor for PD-1 inhibitor-associated hepatotoxicity¹, but underlying mechanisms remain unclear. In this study, quantitative systems toxicology (QST) modeling was performed to investigate susceptibility and mechanism of nivolumabinduced hepatotoxicity in MASLD patients.

By Kyunghee Yang, Lara Clemens, Lawrence A. Vernetti, Mark T. Miedel, Michael W. Castiglione, D. Lansing Taylor, Allison Cruikshank, Leyi Zhang, Francisco Huizar, Celeste Vallejo,
Lisl K.M. Shoda, James J. Beaudoin

ASCPT 2026 Annual Meeting, March 4-6 in Denver, CO